Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Nervous system diseases

Dementia drug could help prevent falls in Parkinson’s disease patients

Patients with Parkinson’s disease were 45% less likely to fall after taking rivastigmine than those receiving placebo in a study.

The acetylcholinesterase inhibitor rivastigmine, a drug commonly prescribed to treat dementia could help prevent falls in patients with Parkinson’s disease, research finds. In the image, MRI brain scan of a patient with Parkinson's disease

Source: Zephyr / Science Photo Library

Researchers suggest that rivastigmine’s positive effects on gait variability in Parkinson’s disease might be mediated via improved cognition

A drug commonly prescribed to treat dementia could help prevent falls in patients with Parkinson’s disease, according to research published in The Lancet Neurology[1] on 12 January 2015.

Researchers from the University of Bristol found that patients with Parkinson’s disease who were given the acetylcholinesterase inhibitor rivastigmine — usually prescribed for dementia — were 45% less likely to fall and were steadier when walking compared with those who received placebo.

“To our knowledge, this is the first trial to show that rivastigmine can improve gait stability and might reduce falls in patients with Parkinson’s disease, and has acceptable tolerability and safety consistent with previous work,” they say.

The researchers recruited 130 patients with Parkinson’s disease who had fallen at least once in the past year but who could walk 18 metres unaided; none had dementia or had ever taken an acetylcholinesterase inhibitor. Patients were randomised to receive rivastigmine uptitrated from 3mg per day to 12mg per day over 12 weeks (n=65) or placebo (n=65).

The researchers recorded gait variability, the stride-to-stride fluctuations in walking, experienced by the study participants at baseline and after 32 weeks of treatment. Participants were tested under three conditions: walking normally; walking while performing a simple verbal task; and walking while performing a more complex verbal task.

Compared with placebo, step time variability for normal walking among patients taking rivastigmine was 28% lower (P=0.002) and step time variability for walking while doing the simple task was 21% lower (P=0.045). Improvements in step time variability for the more complex task did not differ between the two groups (P=0.17).

One participant in the rivastigmine group had an extremely high number of falls (1,122 falls during the treatment period) and was removed from the analysis of fall rate. Excluding this outlier, median fall rate in the rivastigmine group was 0.50 (interquartile range 0.14–0.89), compared with 1.14 (0.27–2.6) in the placebo group.

“This is a very exciting piece of work for Parkinson’s disease patients as gait stability and falls are a huge problem for this patient group,” says Janine Barnes, a neurology specialist pharmacist at Dudley clinical commissioning group in the West Midlands.

However, the results need to be interpreted with caution, she warns. “We need a larger phase III randomised controlled trial with falls as the primary outcome before we consider rivastigmine in the management of falls in patients with Parkinson’s disease,” she adds.

Joela Mathews, a specialist neuroscience pharmacist at Barts Health NHS Trust, Royal London Hospital, says that if results from phase III trials are positive, commissioners should review rivastigmine’s use “taking into account the reduced hospitalisation of patients due to the decreased number of falls”.

“The only current effective treatment for gait instability in Parkinson’s disease is based on physiotherapy and includes dance therapy,” explains Mathews. Gait instability is often the first symptom a patient suffers from and is associated with falls that lead to hospital admissions, she adds.

The researchers say more research is needed to determine the mechanism behind rivastigmine’s effect, which they suggest is likely to have resulted from improvements in gait variability, velocity and balance.

“This gain might or might not be mediated via improved cognition, specifically improved attention to compensate for impaired gait resulting from striatal dopaminergic loss, or via a direct effect on gait,” they say.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200482

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • The acetylcholinesterase inhibitor rivastigmine, a drug commonly prescribed to treat dementia, could help prevent falls in patients with Parkinson’s disease, research finds. In the image, MRI brain scan of a patient with Parkinson's disease

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.